Recent global health problems and new infectious diseases show that traditional vaccine platforms have significant challenges, like being slow to adapt, not being able to control antigen presentation well, and requiring a cold chain. DNA origami is a new nanotechnology platform aims to address these gaps by providing precise, programmable antigen display and offering improved control over immunogenicity compared to some existing methods. This review involves a close look at DNA origami-based immunoscaffolds, focusing on their structural design, immunological mechanisms, and potential advantages compared to traditional vaccine technologies like mRNA, protein subunits, and viral vectors. Recent preclinical studies demonstrate that DNA origami enables precise control of antigen valency, geometry, and multivalent presentation, which can enhance B- and T-cell responses and may reduce carrier immunogenicity. The review also discusses key engineering considerations, including structural stability, biocompatibility, scalability of manufacturing, and potential for mucosal and oral delivery. These aspects highlight both the translational opportunities, and the practical challenges associated with DNA origami vaccines. These factors show both translational opportunities and practical challenges. New structural patterns, like double-crossover (DX) molecules and DNA tubes, make DNA origami platforms even more flexible, stable, and complex in terms of their functions. A few challenges still need to be overcome, such as regulatory pathways, scaffold immunogenicity, and manufacturing costs, even though the preclinical results against infectious diseases (like SARS-CoV-2 and HIV) and cancer models appear positive. In general, DNA origami immunoscaffolds represent a highly programmable platform with significant potential for next-generation vaccine and therapy development.
Purohit et al. (Fri,) studied this question.